Patient Capital Management LLC Invests $60.72 Million in Illumina, Inc. $ILMN

Patient Capital Management LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 345,314 shares of the life sciences company’s stock, valued at approximately $60,717,000. Illumina comprises about 2.0% of Patient Capital Management LLC’s investment portfolio, making the stock its 23rd biggest position.

Several other institutional investors and hedge funds have also made changes to their positions in ILMN. Elyxium Wealth LLC acquired a new position in shares of Illumina during the 4th quarter valued at about $25,000. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina during the 4th quarter valued at $26,000. Laurel Wealth Advisors LLC acquired a new stake in Illumina in the 4th quarter valued at $26,000. Activest Wealth Management raised its position in Illumina by 671.9% in the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 215 shares during the period. Finally, Keating Financial Advisory Services Inc. purchased a new position in Illumina in the second quarter valued at about $32,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ILMN. Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 3rd. Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Barclays raised their target price on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a report on Friday, July 31st. Stifel Nicolaus boosted their price target on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Leerink Partners upped their price target on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average price target of $188.40.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Illumina Stock Performance

NASDAQ:ILMN opened at $219.40 on Monday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm has a 50-day moving average of $188.01 and a two-hundred day moving average of $152.52. The stock has a market cap of $33.13 billion, a P/E ratio of 40.93, a PEG ratio of 3.09 and a beta of 1.45. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $220.43.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the previous year, the company earned $1.19 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Illumina news, Director Keith A. Meister sold 299,336 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $217.96, for a total value of $65,243,274.56. Following the transaction, the director directly owned 1,409,851 shares of the company’s stock, valued at $307,291,123.96. This represents a 17.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Patricia Leckman sold 783 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,095,958 shares of company stock worth $401,720,974 in the last quarter. Company insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.